← Eichor
Condition: Idh Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Idh Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tuvusertib in Astrocytoma With ATRX Mutation
Phase 2 · 10 location(s) · Grupo Español de Investigación en Neurooncología · NCT07417761Metabolic Characterization of Space Occupying Lesions of the Brain
Phase N/A · 1 location(s) · Insel Gruppe AG, University Hospital Bern · NCT04233788ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
Phase N/A · 1 location(s) · Daping Hospital and the Research Institute of Surgery of the · NCT07405372PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
NA · 1 location(s) · Oslo University Hospital · NCT05190172A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Phase 3 · 53 location(s) · Hutchmed · NCT06387069A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) M
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05588141All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Phase 2 · 1 location(s) · Stephen Bagley, MD, MSCE · NCT05345002Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Phase N/A · 1 location(s) · Erasmus Medical Center · NCT06180434Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Phase 2 · 12 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07260175Non-invasive Glioma Characterization Through Molecular Imaging
NA · 1 location(s) · University of Miami · NCT03684109Study of How Safe and Effective Tarlatamab is in Brain Cancers
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT06776250Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · 82 location(s) · Alliance for Clinical Trials in Oncology · NCT07215910Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Comp
Phase N/A · 1 location(s) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · NCT07547163IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML P
Phase 2 · 4 location(s) · Alice Mims · NCT05401097Window of Opportunity Study of DSP-0390 in Gliomas
EARLY_Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06636162
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.